Anti-IL-5 therapy and the airway microbiome in asthma.

A. Sullivan (Cork, Ireland), C. Ward (Newcastle upon Tyne, United Kingdom), D. Casey (Cork, Ireland), D. Flynn (Cork, Ireland), E. Hunt (Cork, Ireland), J. Eustace (Cork, Ireland), P. O' Byrne (Hamilton, Ontario, Canada), B. Plant (Cork, Ireland), J. Macsharry (Cork, Ireland), D. Murphy (Cork, Ireland)

Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Session: Recent innovations regarding the mechanisms and treatments of asthma
Session type: Oral Presentation
Number: 5279
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Sullivan (Cork, Ireland), C. Ward (Newcastle upon Tyne, United Kingdom), D. Casey (Cork, Ireland), D. Flynn (Cork, Ireland), E. Hunt (Cork, Ireland), J. Eustace (Cork, Ireland), P. O' Byrne (Hamilton, Ontario, Canada), B. Plant (Cork, Ireland), J. Macsharry (Cork, Ireland), D. Murphy (Cork, Ireland). Anti-IL-5 therapy and the airway microbiome in asthma.. 5279

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The impact of anti-IgE treatment on the airway microbiome in asthma.
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020




Neuroregulatorial therapy of bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 55s
Year: 2002

Same role and same treatment for airway eosinophilia in asthma and COPD?
Source: Eur Respir J 2007; 29: 831-833
Year: 2007


The airway microbiota and exacerbations of COPD
Source: ERJ Open Res, 6 (3) 00168-2020; 10.1183/23120541.00168-2020
Year: 2020



IL-33 and airway remodelling in paediatric severe therapy resistant asthma
Source: Annual Congress 2012 - Severe asthma and developing allergy in childhood
Year: 2012

A study to define the microbiome of the asthmatic airway.
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017

Involvement of airway eosinophilia and airway hyperresponsiveness in management and therapy for COPD>
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020

Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives
Source: Eur Respir Rev 2015; 24: 594-601
Year: 2015



Effect of montelukast on excessive airway narrowing in adult asthmatics not on controller therapy
Source: Annual Congress 2006 - New developments in the treatment and management of asthma
Year: 2006


Effects of budesonide/formoterol maintenance therapy on airway hyperresponsiveness and inflammation in an allergic rat model
Source: Eur Respir J 2004; 24: Suppl. 48, 351s
Year: 2004

Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial
Source: Eur Respir J 2007; 30: 457-466
Year: 2007



Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009

Heterogeneous response of airway eosinophilia to biologics in severe asthma patients
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021


The influence of obesity on bronchial hyperresponsiveness, airway and systemic inflammation, lung function and quality of life in patients with asthma
Source: Annual Congress 2008 - Asthma: growing understanding of influential factors
Year: 2008

Sublingual monomeric allergoid immunotherapy improves airway inflammation, airway hyperresponsiveness and clinical symptoms in allergic rhinitis and asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 439s
Year: 2006

Changes in symptoms, respiratory function, airway inflammation, and airway hyperresponsiveness over 10 year of inhaled corticosteroid therapy in adult asthma patients
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Source: Eur Respir J 2001; 18: 254-261
Year: 2001



The burden of airway hyperresponsiveness on the control of asthma
Source: Annual Congress 2011 - Update on monitoring airway diseases
Year: 2011


The airway microbiota is significantly altered in asthma patients with airway hyperresponsiveness to mannitol
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015